CNS Pharma boosts ATM equity facility from $5.2M to $30.2M; $5.19M already sold

CNS Pharmaceuticals, Inc.

On July 30, 2024, CNS Pharmaceuticals increased the aggregate sales price under its ATM agreement to $25M, for a total of $30.2M including original $5.2M.
As of July 30, 2024, the Company sold 7,206,743 shares for gross proceeds of approximately $5.19 million.
Outstanding shares as of July 30, 2024: 10,075,017; remaining capacity implies significant potential dilution.
Sales are conducted through A.G.P./Alliance Global Partners under an effective S-3 shelf registration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.